drugset

drugset / Trial / NCT02228525

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

NCT02228525 ↗

Phase 2 Completed 25 enrolled Memorial Sloan Kettering Cancer Center Columbia University · collab Karyopharm Therapeutics Inc · collab M.D. Anderson Cancer Center · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.

Timeline

Start: 2014-08-27
Primary completion: 2021-04-06
Completion: 2021-04-06

Publications

Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, Chung SS, Rampal RK, Park JH, Stein EM, Tallman MS, Sen F, Gonen M, Abdel-Wahab O, Klimek VM. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2020 Aug;7(8):e566-e574. doi: 10.1016/S2352-3026(20)30209-X.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selinexor	Other / unclassified	60 mg	Oral

Indications